Phage Therapy to Control Pathogenic Bacteria, 2nd Edition

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Bacteriophages".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 8655

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biology and CESAM, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal
Interests: bacteriophages; phage therapy; pathogenic bacteria; multidrug resistance bacteria; alternative approaches to antibiotics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Departamento de Biologia, CESAM - Centro de Estudos do Ambiente e do Mar, Campus Universitário de Santiago, Universidade de Aveiro, 3810-193 Aveiro, Portugal
Interests: phage therapy; antimicrobial photodynamic therapy; alternative approaches to antibiotics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first volume of the Special Issue “Phage Therapy to Control Pathogenic Bacteria” was published in 2021. It is a successful Issue with ten published papers and has encouraged us to open a second volume with the same topic.

As a continuation of the Special Issue published in 2021, this second volume will also deliver an invaluable compendium of the latest approaches and challenges associated with the development of phage therapy. Topics may include but are not limited to recent advances in bacteriophage research for bacterial disease control in different areas (veterinary medicine, food industry, agriculture, aquaculture, and human medicine).

Dr. Carla Pereira
Prof. Dr. Adelaide Almeida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bacteriophages
  • bacteriophage therapy
  • human infections
  • animal infections
  • plant infections
  • phage pharmacokinetics
  • combination therapies
  • biofilm control
  • phage resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1644 KiB  
Article
Prolongation of Fate of Bacteriophages In Vivo by Polylactic-Co-Glycolic-Acid/Alginate-Composite Encapsulation
by Sang-Guen Kim, Sib Sankar Giri, Su-Jin Jo, Jeong-Woo Kang, Sung-Bin Lee, Won-Joon Jung, Young-Min Lee, Hee-Jin Kim, Ji-Hyung Kim and Se-Chang Park
Antibiotics 2022, 11(9), 1264; https://doi.org/10.3390/antibiotics11091264 - 17 Sep 2022
Cited by 8 | Viewed by 2138
Abstract
With concern growing over antibiotics resistance, the use of bacteriophages to combat resistant bacteria has been suggested as an alternative strategy with which to enable the selective control of targeted pathogens. One major challenge that restrains the therapeutic application of bacteriophages as antibacterial [...] Read more.
With concern growing over antibiotics resistance, the use of bacteriophages to combat resistant bacteria has been suggested as an alternative strategy with which to enable the selective control of targeted pathogens. One major challenge that restrains the therapeutic application of bacteriophages as antibacterial agents is their short lifespan, which limits their antibacterial effect in vivo. Here, we developed a polylactic-co-glycolic acid (PLGA)/alginate-composite microsphere for increasing the lifespan of bacteriophages in vivo. The alginate matrix in PLGA microspheres encapsulated the bacteriophages and protected them against destabilization by an organic solvent. Encapsulated bacteriophages were detected in the tissue for 28 days post-administration, while the bacteriophages administered without advanced encapsulation survived in vivo for only 3–5 days. The bacteriophages with extended fate showed prophylaxis against the bacterial pathogens for 28 days post-administration. This enhanced prophylaxis is presumed to have originated from the diminished immune response against these encapsulated bacteriophages because of their controlled release. Collectively, composite encapsulation has prophylactic potential against bacterial pathogens that threaten food safety and public health. Full article
(This article belongs to the Special Issue Phage Therapy to Control Pathogenic Bacteria, 2nd Edition)
Show Figures

Figure 1

Review

Jump to: Research

33 pages, 634 KiB  
Review
Bacteriophages in the Control of Aeromonas sp. in Aquaculture Systems: An Integrative View
by Carla Pereira, João Duarte, Pedro Costa, Márcia Braz and Adelaide Almeida
Antibiotics 2022, 11(2), 163; https://doi.org/10.3390/antibiotics11020163 - 27 Jan 2022
Cited by 20 | Viewed by 5326
Abstract
Aeromonas species often cause disease in farmed fish and are responsible for causing significant economic losses worldwide. Although vaccination is the ideal method to prevent infectious diseases, there are still very few vaccines commercially available in the aquaculture field. Currently, aquaculture production relies [...] Read more.
Aeromonas species often cause disease in farmed fish and are responsible for causing significant economic losses worldwide. Although vaccination is the ideal method to prevent infectious diseases, there are still very few vaccines commercially available in the aquaculture field. Currently, aquaculture production relies heavily on antibiotics, contributing to the global issue of the emergence of antimicrobial-resistant bacteria and resistance genes. Therefore, it is essential to develop effective alternatives to antibiotics to reduce their use in aquaculture systems. Bacteriophage (or phage) therapy is a promising approach to control pathogenic bacteria in farmed fish that requires a heavy understanding of certain factors such as the selection of phages, the multiplicity of infection that produces the best bacterial inactivation, bacterial resistance, safety, the host’s immune response, administration route, phage stability and influence. This review focuses on the need to advance phage therapy research in aquaculture, its efficiency as an antimicrobial strategy and the critical aspects to successfully apply this therapy to control Aeromonas infection in fish. Full article
(This article belongs to the Special Issue Phage Therapy to Control Pathogenic Bacteria, 2nd Edition)
Back to TopTop